Key Drivers
- High gross margin
- Persistent cash burn
- Rich valuation
AIAI Summary
Rhythm has shifted from R&D optionality to a commercial-stage valuation where high product gross margins mean the investment hinges on execution—monitor IMCIVREE uptake, payer coverage/prior-authorization progress, and cash burn versus revenue cadence rather than just clinical binary readouts. The single biggest lever: successful label expansion and payer access can rapidly convert margins into positive operating cash flow, while EMANATE subgroup ambiguity or slow reimbursement would likely force dilution and significant downside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High gross margin
- •Persistent cash burn
- •Rich valuation
RYTM combines very high gross margins and ample short-term liquidity with unsustainable cash burn from R&D/SG&A that drives operating losses, negative free cash flow and a stretched market valuation.
Price Behavior
Key Price Behavior Insights:
- •Price below MA
- •Mid-$80s support
- •Low-90s resistance
RYTM is in a short-term downtrend after falling ~12–13% from $99.78 to $87.45 over the last month, trading below the last-month moving average with mid-$80s support and resistance near the low-$90s (and stronger near the high-$90s/low-$100s).
~12–13% drop from $99.78 to $87.45 over the last month
Sentiment & News
Key News Insights:
- •FDA approval
- •Mixed trials
- •Revenue growth
Rhythm reported mixed clinical data but achieved FDA approval and commercial readiness for IMCIVREE while delivering strong FY25 revenue growth and prompting investor activity and stock volatility.
FDA approval and specialty‑pharmacy alignment should support near‑term commercial uptake despite mixed trial signals that may temper upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings